Esmo 2022 – the new liver cancer entrants line up
Late-breakers give tislelizumab, camrelizumab and Keytruda outside chances to add to the first-line armamentarium.
No place for Wee1 in Astra’s synthetic lethality work
Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.
Scholar Rock’s quest for a better TGF-β drug
Biomarkers and precise targeting could help the anti-TGF-β1 antibody SRK-181 succeed where bintrafusp failed, the group hopes.
Biopharma’s stock market winners of 2021 revealed
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
